Bei Akademie registrieren
Regeneron, US75886F1075

Regeneron reports Libtayo survival data. Regeneron stock costs EUR 718.60.

Published on 10/25/2026 at 17:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Regeneron stock costs EUR 718.60 in weekend trading on October 25, 2026. Libtayo data showed a 37 percent lower death risk at 44 months.

Libtayo data and weekend trading

  • On October 25, 2026, Regeneron reported a 37 percent reduction in death risk at 44 months.
  • Regeneron stock trades at EUR 718.60 at 5:33 p.m. CEST on October 25, 2026, according to Lang & Schwarz.
  • The C-POST trial enrolled 415 patients who received Libtayo or placebo for up to 48 weeks.
Trading-Floor mit Händlern vor Bildschirmen mit steigenden Biotech-Aktiencharts
Regeneron Pharma US75886F1075 zeigt ein Börsen-Editorial mit belebtem Trading-Floor und steigenden Biotech-Sektor-Charts auf Bildschirmen, Illustration mit AI erstellt.

On October 25, 2026, Regeneron Pharmaceuticals announced longer-term Libtayo data from the Phase 3 C-POST trial. The company said the data showed a 37 percent reduction in the risk of death at a median follow-up of 44 months. The results were presented at the European Society for Medical Oncology Congress 2026. Regeneron Pharmaceuticals published the release.

Market context: Market report S&P 500.

Weekend trading

Lang & Schwarz quoted Regeneron at EUR 718.60 in weekend trading at 5:33 p.m. CEST on October 25, 2026. The bid was EUR 717.90 and the ask was EUR 719.30. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Regeneron stock.

C-POST trial data

Regeneron said the overall-survival benefit increased from a 14 percent reduction in the risk of death at 24 months and 22 percent at 30 months to 37 percent at 44 months. The company also reported that 61 of 69 placebo patients who experienced a recurrence subsequently received Libtayo. The trial enrolled 415 patients and evaluated treatment for up to 48 weeks. The company release said disease-free survival improved regardless of baseline minimal residual disease status.

Next Xetra session

The next Xetra session is scheduled for October 26, 2026. Regeneron's common stock is listed on the Nasdaq Global Select Market under the symbol REGN, according to the company's October 6, 2026 Form 8-K. The filing also reported a $1.0 billion upfront payment expected under an expanded Sanofi collaboration announced on October 1, 2026.

Disclaimer...
en | US75886F1075 | REGENERON | boerse | 70410330 | bgmi